[EN] COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON OTHER E3 UBIQUITIN LIGASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR INDUIRE DES MODIFICATIONS CONFORMATIONNELLES DANS CÉRÉBLON ET D'AUTRES UBIQUITINE LIGASES E3
申请人:CELGENE CORP
公开号:WO2015200795A1
公开(公告)日:2015-12-30
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cerebloR, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
申请人:Celgene Corporation
公开号:US20150374678A1
公开(公告)日:2015-12-31
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
The present invention relates to 5-substituted isoindoline compounds of formula (III)
or formula (IV)
wherein R10, R11, R13, R14, X and Y are as defined herein; or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof. The present invention also relates to a pharmaceutical composition of the compounds of the invention. The present invention also relates to a compound of the invention for use in treating, managing or preventing disease conditions as disclosed herein.
A combination of lenalidomide and artesunate/artemisone for treating cancer
申请人:CELGENE CORPORATION
公开号:EP2851070A1
公开(公告)日:2015-03-25
Provided herein is an immunomodulatory compound for use in a method of treating cancer, wherein the method comprises administering the immunomodulatory compound, and administering an artemisinin derivative, wherein the immunomodulatory compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and the artemisinin derivative is artesunate or artemisone.